| 34.51 2.617 (8.21%) | 07-02 15:54 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.3 |
1-year : | 47.07 |
| Resists | First : | 34.5 |
Second : | 40.3 |
| Pivot price | 30.67 |
|||
| Supports | First : | 29.8 |
Second : | 26.9 |
| MAs | MA(5) : | 32.41 |
MA(20) : | 30.34 |
| MA(100) : | 31.3 |
MA(250) : | 0 | |
| MACD | MACD : | 0.8 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 92 |
D(3) : | 90 |
| RSI | RSI(14): 70.9 |
|||
| 52-week | High : | 38.08 | Low : | 25.17 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TBXU ] has closed above the upper band by 18.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 32.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.55 - 34.69 | 34.69 - 34.8 |
| Low: | 33.14 - 33.31 | 33.31 - 33.46 |
| Close: | 34.22 - 34.49 | 34.49 - 34.73 |
This Direxion Daily Biotech Top 5 Bull 2X ETF aims to provide daily investment returns equivalent to 200% of the performance of the NYSE Biotechnology Top 5 Equal Weight Index, before factoring in its fees and expenses. Please note that the fund offers no assurance of consistently meeting its stated investment targets.
Sun, 17 May 2026
From Rough Stretch to Breakthrough Era: Trade 5 of Biotech's Leading Stocks With 2X Daily Leverage - Barchart.com
Wed, 06 May 2026
BIOY Stock Fund Price and Chart — NASDAQ:BIOY - TradingView
Tue, 28 Apr 2026
Biotech, Banks, and Bonds: Trading the Fed’s April Meeting - Direxion
Wed, 04 Feb 2026
MRNX Stock Fund Price and Chart — AMEX:MRNX - TradingView
Fri, 23 Jan 2026
LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF (NYSEARCA:LABU) - Seeking Alpha
Fri, 28 Nov 2025
Can Biotech’s Top 5 Revive the Sector’s Pulse? - Direxion
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management - Leveraged
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|